Loading

Please wait...

Tresiba Flextouch

Tresiba flextouch Prescription
Generic Name: insulin degludec (IN su lin de GLOO dek)
Brand Names: Tresiba
Tresiba (insulin degludec) is used to treat diabetes mellitus. Includes Tresiba side effects, interactions and indications.
  • Prescription Settings
  • X
  • medly Free, same-day prescription delivery to your doorstep is available in your area.
  • Learn more
  • Local Pharmacy Pickup available at . Pick up your medication at any of our participating pharmacies.
  • Mail Order Home Delivery available at , the easiest way to receive your medications.

Tresiba Flextouch Coupons & Prices

Set your location
for drug prices near you

Enter your zip code

Please wait while the prices are loaded...
Click here to try again.

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Tresiba Flextouch Drug Information:

Tresiba (insulin degludec) is a long-acting insulin that starts to work several hours after injection and keeps working evenly for 24 hours. Insulin is a hormone that works by lowering levels of glucose (sugar) in the blood. Tresiba is used to improve blood sugar control in adults with Diabetes mellitus. Tresiba may be used for type 1 or type 2 Diabetes. Tresiba is supplied in a multiple-dose vial or as a single-patient-use FlexTouch pen. Tresiba FlexTouch is a disposable prefilled disposable pen available in two different strengths, U-100 (100 units/mL) containing 300 units of insulin and U-200 (200 units/mL) containing 600 units of insulin. Learn more

Buy Tresiba flextouch Online and Tresiba flextouch Delivery

USARx offers the following ways to purchase this medication. Choose the Best option for you!

  • Guaranteed Price

    Local Pharmacy Pickup of Tresiba flextouch

    Pay this amount and pick up your prescription at ANY Retail pharmacy of your choice! Walgreens, CVS, Walmart, etc.

  • 30-day supply
    90-day supply

    Mail Order Home Delivery of Tresiba flextouch

    The easiest way to receive your medications.

Tresiba flextouch Medicare Coverage

Tresiba flextouch Medicare Overview

Does Medicare cover Tresiba flextouch?

Yes

65% of Medicare Part D and Medicare Advantage plans cover this drug.
How much is my Tresiba flextouch co-pay with Medicare?

It depends. Which coverage stage are you in? Click on a tab below…

CO-PAY RANGE

$5 – $587

In the Deductible co-pay stage, you are responsible for the full cost of your prescriptions. Your Medicare deductible cannot exceed $360 in 2016.

Ways to Save on Tresiba flextouch

Here are some ways that may lower the cost of your tresiba flextouch prescription.

  • Instead of Medicare, Use a USA Rx Coupon

    If your Medicare co-pay is higher, you can save money by using a USARx coupon instead.

Tresiba Flextouch Side Effects

Note: This document contains side effect information about insulin degludec. Some of the dosage forms listed on this page may not apply to the brand name Tresiba.

For the Consumer

Applies to insulin degludec: subcutaneous solution

Along with its needed effects, insulin degludec (the active ingredient contained in Tresiba) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking insulin degludec:

Less common

  • Bloating or swelling of the face, arms, hands, lower legs, or feet
  • rapid weight gain
  • tingling of the hands or feet
  • unusual weight gain or loss

Incidence not known

  • Anxiety
  • blurred vision
  • chills
  • cold sweats
  • confusion
  • convulsions
  • cool, pale skin
  • cough
  • decreased urine
  • depression
  • difficulty with swallowing
  • dizziness
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • dry mouth
  • fast heartbeat
  • headache
  • hives, itching, or skin rash
  • increased hunger
  • increased thirst
  • irregular heartbeat
  • large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
  • loss of appetite
  • muscle pain or cramps
  • nausea or vomiting
  • nightmares
  • numbness or tingling in the hands, feet, or lips puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • shakiness
  • slurred speech
  • sweating
  • tightness in the chest
  • unusual tiredness or weakness

Some side effects of insulin degludec may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Abdominal or stomach pain
  • body aches or pain
  • diarrhea
  • dry mouth
  • ear congestion
  • fever
  • headache
  • loss of voice
  • nasal congestion
  • nausea or vomiting
  • runny nose
  • sneezing
  • sore throat

Incidence not known

  • Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
  • redistribution or accumulation of body fat

For Healthcare Professionals

Applies to insulin degludec: subcutaneous solution

General

The most commonly reported adverse reactions include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema, and weight gain.

Metabolic

Weight gain, attributed to the anabolic effects of insulin, has been reported. In 52-week clinical trials, an average weight gain of 1.8 kg and 3 kg was reported in patients with type 1 diabetes and type 2 diabetes, respectively.

Very common (10% or more): Hypoglycemia

Frequency not reported: Weight gain

Cardiovascular

In clinical trials, peripheral edema was reported in 3% and 0.9% of patients with type 1 diabetes and type 2 diabetes, respectively.

Common (1% to 10%): Peripheral edema

Local

Common (1% to 10%): Injection site reactions

Injection site reactions have included injection site hematoma, pain, hemorrhage, erythema, nodules, swelling, discoloration, pruritus, warmth, and injection site mass. These reactions are usually mild and transient and disappear with continued treatment.

Hypersensitivity

Uncommon (0.1% to 1%): Hypersensitivity (manifested with swelling of tongue and lips, diarrhea, nausea, tiredness, and itching) and urticaria

Dermatologic

Uncommon (0.1% to 1%): Lipodystrophy, urticaria

Immunologic

Insulin administration may cause anti-insulin antibodies to form. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay and may be influenced by several factors such as: assay methodology, sample handling, timing of sample collection, concomitant medication, and underlying disease. It is for these reasons, comparisons with antibodies in other studies or to other products may be misleading.

In a study of adult insulin-experienced type 1 diabetes patients, 68.9% of patients receiving this were positive at baseline for anti-insulin degludec (the active ingredient contained in Tresiba) antibodies and 12.3% of the patients developed anti-insulin degludec antibodies at least once during the study. In pediatric insulin-experienced patients with type 1 diabetes, 84.1% of those were positive at baseline for anti-insulin degludec antibodies and 5.8% of patients developed anti-insulin degludec antibodies at least once during the study. Between 96.7% and 99.7% of patients who were positive for anti-insulin degludec antibodies were also positive for anti-human insulin antibodies.

Frequency not reported: Anti-insulin antibodies

Respiratory

Very common (10% or more): Nasopharyngitis (23.9%), upper respiratory tract infection (11.9%)

Common (1% to 10%): Sinusitis

Nervous system

Very common (10% or more): Headache (11.8%)

Gastrointestinal

Common (1% to 10%): Gastroenteritis, diarrhea

Editorial References and Review

Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.

Source: Drugs.com Tresiba Flextouch (www.drugs.com/tresiba.html).